A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
Sminu Bose(Memorial Sloan Kettering Cancer Center), Matthew Ingham(Columbia University), Brian A. Van Tine(Washington University in St. Louis), Gary K. Schwartz(Baylor University Medical Center), Mia C. Weiss(Washington University in St. Louis), Naomi Sender(Columbia University Irving Medical Center), Mark Agulnik(Northwestern University), Shing M. Lee(Columbia University), Frank J. Hsu(Apexigen (United States)), Sarah Sta Ana(Columbia University Irving Medical Center), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Liner Ge(Columbia University)
Cited by 2
Related Papers
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
|Journal of Clinical Oncology|2005|1.1k
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573